Teva Releases Q2 2026 Aide Memoire
Rhea-AI Summary
Teva (NYSE:TEVA) announced its Q2 2026 Aide Memoire is now available on the investors page of its website. The document compiles previously disclosed public information to help investors prepare for second quarter 2026 results, expected on July 29, 2026, at 7:00 a.m. ET, followed by an earnings conference call at 8:00 a.m. ET.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – TEVA
On the day this news was published, TEVA gained 2.29%, reflecting a moderate positive market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $806M to the company's valuation, bringing the market cap to $36.02B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
TEVA was down -3.32% on elevated volume, while several high-affinity peers (e.g., UTHR, VTRS, NBIX, TAK) also traded lower, but scanner data did not flag a coordinated sector momentum move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 10 | Pipeline acquisition | Positive | -2.5% | Closed Emalex Biosciences deal, adding late-stage Tourette syndrome asset to pipeline. |
| Jun 08 | Clinical data update | Positive | -2.3% | Long-term AUSTEDO data highlighted sustained tardive dyskinesia treatment benefits. |
| Jun 05 | Clinical data update | Positive | -0.7% | Real-world AUSTEDO data showed Huntington’s chorea and quality-of-life improvements. |
| Jun 04 | Product launch | Positive | +4.9% | Launched AHZANTIVE aflibercept biosimilar across several European markets. |
| Jun 01 | Conference appearance | Neutral | -4.5% | Announced participation in Goldman Sachs Global Healthcare Conference fireside chat. |
Recent news has often been followed by negative price reactions, even on seemingly positive operational updates.
Regulatory & Risk Context
Reported short interest appears relatively low, suggesting limited short-squeeze dynamics and generally moderate incremental volatility risk from positioning alone.
Market Pulse Summary
This announcement directs investors to Teva’s Q2 2026 aide memoire ahead of results on July 29, framing expectations using prior performance and outlook. Key watchpoints remain earnings quality, leverage and progress on its Pivot to Growth strategy.
AI-generated analysis. Not financial advice.
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the “Investors” page on its website.
Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of second quarter 2026 results, which are expected to be released on Wednesday, July 29, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day. This document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and the Aide Memoire document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, and in our Quarterly Report on Form 10-Q for the first quarter of 2026, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries
TevaIR@Tevapharm.com
